Louise S. Clemmensen
Scientific Developer

Bringing ideas to life and research to market
Bringing science to market

The situation
- The Nordic is home to world-class life science research
- Increasing number of patent applications

However
- Denmark has limited success in translating life-science research into new products and solutions
- In the ecosystem, there is very limited support dedicated to the early stages of life-science start-up development
Bringing science to market

BII is a Novo Nordisk Foundation initiative:

• Established in January 2018
• Granted DKK 392 million for a 3-years establishment period
• Our main focus is **pharma (therapeutics), medtech and industrial biotech**
• BII does not work for profit
Life science entrepreneur?

BII has everything you need

BII

Funding

Entrepreneurial culture

Mentors & experts

Programs & Support

2300 m2 labs and offices

Global network (investors & partnerships)
**BII Labs**

375 m² open GMO 1 classified **general** lab

150 m² open GMO 1 classified **special** labs
  - DNA/RNA lab
  - Microscope lab
  - Cell labs
  - One GMO 2 lab

60 m² open workshop
**BII Open Call Programs 2020**

**Proof of Concept**
- Establish technical feasibility
- Grants of up to 1M DKK (up to 10 grants per call)
- Researchers at Danish universities/hospitals
- Located at host research institution
- Deadline: **12. March 2020**
  Last call at BII

**Business Acceleration Academy**
- Validate commercial potential
- Grants of up to 350K DKK (up to 8 grants per call)
- Life science spin-outs CVR registered in DK
- Located at BII
- New program under development – opens in fall

**Preseed**
- Address early stage technical or commercial risks
- Grants (academic) or loans (startups) of up to 3.5M DKK (up to 7)
- Researchers at Nordic universities/hospitals or startups CVR registered in DK
- Located at host research institution or BII
- Deadline: **4. June 2020**
  Call opens 16. March

**Creation House**
- De-risking project to attract financing
- Convertible loan of up to 10M DKK (2-4 per call)
- Researchers at Danish universities/hospitals or life science spin-outs CVR registered in DK
- Located at BII
- Call opens in spring
  Deadline: Mid august (TBD)
Proof of Concept

Goal: Stimulate innovation within academia by allowing researchers to establish technical feasibility

Who is it for?
• Researchers at Danish universities and/or hospitals with a very early pharma (therapeutics), medtech and bioindustrial project that are ready to establish the preliminary proof of concept
• The project must have a clear commercial potential
• Applicants have to be located in Denmark and continue the research at their host institution in Denmark within the duration of 1 year

How is it funded?
• A grant for up to DKK 1M
• The grant will be awarded to the host institution
• BII takes no equity

Deadline: 12. March
Preseed

Goal: To accelerate the maturity of the life science project by addressing early stage technical and commercial risks in order to attract further funding

Who is it for?

- Early innovation projects that have already shown some proof of concept
  
  **Startups**
  - CVR registered in Denmark
  - Primary team members must have the right to reside and work in Denmark at the time of project initiation
  - Owns or has full access to the IPR of their discovery under market terms for early-stage startups

  **Research institutions**
  - Researchers at Nordic universities and/or hospitals
  - Must present a plan for IPR in the event of commercial spinout
  - If any co-applicants from multiple institutions, an IP management agreement must be in place

How is it funded?

- A founder-friendly convertible loan of up to DKK 3.5 million

  - A grant of up to DKK 3.5 million
  - The grant will be awarded to host institution

Call opens 16. March
Deadline: 4. June
Creation House

Goal: To mature and de-risk the company to attract substantial funding

Who is it for?
- Companies in pharma (therapeutics), medtech and bioindustrials that have a solid, initial business plan and the entrepreneurial skills to execute on it
- CVR registered in Denmark
- Accepted companies must relocate to BII’s facilities in Copenhagen
- Control of the IP is a requirement, e.g. through ownership or license agreements

How is it funded?
- Through a founder-friendly convertible loan of up to DKK 10 million paid in tranches over an 18 month period
Current Company Portfolio in Creation House

1. **Synklino**
   - DTU/KU spinout developing a drug candidate that can eradicate CMV to improve transplantation outcome
   - [https://synklino.com/](https://synklino.com/)

2. **Circle biomedical**
   - Medtech startup providing easy on-demand, non-hormonal birth control for women
   - [http://getcircle.co/](http://getcircle.co/)

3. **Kariya Pharmaceuticals**
   - Biotech startup developing a first-in-class, best-in-class, dual-incretin agonist to slow the progression of Parkinson's disease
   - [https://www.kariyapharma.com](https://www.kariyapharma.com)

4. **PANCYROS INSULIN. NATURALLY.**
   - KU spinout (DanStem) developing next generation allogeneic stem cell therapy for type 1 diabetes
   - [http://pancryos.com/](http://pancryos.com/)

5. **InProther**
   - KU spinout developing the world’s first adaptive immunooncology therapy targeting immunosuppressive genes of ancient retroviruses that are activated in cancer
   - [http://inprother.com/](http://inprother.com/)

6. **STipe Therapeutics**
   - AU spinout developing first-in-class sensitizers of the STING pathway as novel immunooncology treatment
   - [http://stipetherapeutics.com/](http://stipetherapeutics.com/)

7. **ADCendo**
   - Rigshospitalet/KU spinout developing first-in-class anti-cancer drug, in the form of an antibody-drug conjugate, for soft-tissue sarcoma
   - [http://adcendo.dk/](http://adcendo.dk/)

8. **ANKRIN**
   - KU spinout developing first-in-class compounds that target essential protein-protein interactions required for error-free DNA damage repair
   - [http://ankrin.com/](http://ankrin.com/)

- **20M EUR Series A in 2019**

- **+4 starting this Spring**
Meet the BII BD Team

Who?
Giles Dudley, Senior Business Developer

When?
16. March (30 min time slots)

Where?
Aarhus University
Katrinebjergvej 107, 8200 Aarhus N
Building 5530, Room 0.2.09 (ground floor)

How?
Sign up by sending e-mail to: Morten Holmager holmager@au.dk
Questions?

www.bioinnovationinstitute.com

Email: lcl@novo.dk